Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

BACKGROUND: Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers for management of lenvatinib treatment have been established. The aim of this study is to identify predictive biomarkers for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Ono, Atsushi, Aikata, Hiroshi, Yamauchi, Masami, Kodama, Kenichiro, Ohishi, Waka, Kishi, Takeshi, Ohya, Kazuki, Teraoka, Yuji, Osawa, Mitsutaka, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Kawaoka, Tomokazu, Abe-Chayama, Hiromi, Zhang, Peiyi, Liu, Songyao, Makokha, Grace Naswa, Tsuge, Masataka, Imamura, Michio, Hayes, C. Nelson, Chayama, Kazuaki
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Early Diagnosis and Therapeutic Advances for Liver Cancer: From Bench to Bedside
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7249573/
https://ncbi.nlm.nih.gov/pubmed/32547646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920922051
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados